Media

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

BONESUPPORT HOLDING AB (publ) – INVITATION TO CONFERENCE CALL AND WEBCAST FOR YEAR-END REPORT 2023

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference